证券代码：002422 证券简称：科伦药业 公告编号：2025-063 四川科伦药业股份有限公司 关于公司 2025 年度中期利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 三、履行决策程序情况及意见 （一）董事会审议程序 四川科伦药业股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开 第八届董事会第八次会议、第八届监事会第七次会议审议通过了《关于公司 2025 年度中期利润分配预案的议案》。现将相关情况公告如下： 一、2025 年半年度利润分配预案 鉴于公司 2025 年上半年当期盈利、累计可分配利润为正；且公司现金流可 以满足正常经营和持续发展的实际需求，为加大对投资者的回报力度，分享经营 成果，公司拟定 2025 年度中期利润分配方案如下： 根据公司 2025 年半年度财务报告（未经审计），2025 年半年度实现合并报 表归属于上市公司股东的净利润 1,000,625,359.00 元，母公司报表净利润 888,010,166.00 元，合并报表期末可供分配的利润为 11,802,754,073.00 元，母公 司 ...

科伦药业公告，：2025年上半年净利润10.006亿元，同比下降44.41%。 ...

四川科伦药业股份有限公司 2025 年半年度报告全文 四川科伦药业股份有限公司 2025 年半年度报告 2025 年 8 月 1 四川科伦药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人刘革新、主管会计工作负责人赖德贵及会计机构负责人(会计 主管人员)黄俊声明：保证本半年度报告中财务报告的真实、准确、完整。 公司可能面临行业政策变化、市场风险、环保风险、研发创新风险、质 量控制风险等，敬请广大投资者注意投资风险。详细内容见本报告"第三节 十、公司面临的风险和应对措施"。 公司经本次董事会审议通过的利润分配预案为：以 1,590,781,208 为基 数，向全体股东每 10 股派发现金红利 1.26 元（含税），送红股 0 股（含税）， 不以公积金转增股本。 2 所有董事均已出席了审议本次半年报的董事会会议。 公司半年度报告所涉及未来计划等前瞻性陈述不构成公司对投资者的实 质承诺，投资者及相关人士均应当对此保持足够的风险 ...

8月28日，科伦药业跌1.11%，截至发稿，报36.49元/股，成交6.99亿元，换手率1.47%，总市值583.13亿 元。科伦药业股价已经连续3天下跌，区间累计跌幅6.65%。 责任编辑：小浪快报 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，四川科伦药业股份有限公司位于四川省成都市青羊区百花西路36号，成立日期2002年5月29 日，上市日期2010年6月3日，公司主营业务涉及开发、生产和销售大输液产品。主营业务收入构成为： 非输液47.22%，输液40.86%，研发项目8.69%，其他(补充)3.24%。 从基金十大重仓股角度 嘉合锦鹏添利混合A（008905）基金经理为于启明、季慧娟。 截至发稿，于启明累计任职时间13年57天，现任基金资产总规模156.9亿元，任职期间最佳基金回报 45.5%， 任职期间最差基金回报0.42%。 季慧娟累计任职时间10年55天，现任基金资产总规模206.49亿元，任职期间最佳基金回报35.33%， 任 职期间最差基金 ...

Group 1 - The core viewpoint of the article highlights the growth in the number of enterprises in the chemical raw materials and chemical products manufacturing industry, which increased by 1,021 to a total of 26,860 enterprises in the first half of 2025, representing a year-on-year growth of 3.95% [1] - The proportion of chemical raw materials and chemical products manufacturing enterprises in the total industrial enterprises is 5.16% [1] - The report referenced is the "2025-2031 China Basic Chemical Raw Materials Industry Market Supply and Demand Situation and Investment Prospects Analysis Report" published by Zhiyan Consulting [1] Group 2 - The data indicates that the threshold for scale industrial enterprises has been raised from an annual main business income of 5 million yuan to 20 million yuan since 2011 [1] - Zhiyan Consulting is recognized as a leading industry consulting agency in China, providing comprehensive industry research reports, business plans, feasibility studies, and customized services [1] - The consulting firm emphasizes its commitment to delivering quality services and market insights to empower investment decisions [1]

Core Viewpoint - The article highlights the significant style drift observed in the public fund "Baoying Modern Service Industry Mixed Fund," which has deviated from its stated investment theme, focusing heavily on the pharmaceutical and technology sectors instead of modern services [1][10]. Fund Performance and Holdings - As of the end of Q2 2025, the fund's top ten holdings are predominantly in the pharmaceutical and technology sectors, with a notable concentration in stocks like Kelun-Bio and Tencent Holdings, indicating a high industry concentration [1][2]. - The fund has shown high volatility and elasticity, achieving a return of 64.73% since the beginning of 2025 and 73.28% over the past year, ranking well among peers. However, it has experienced declines in previous years, with losses of 11.91% in 2021, 9.32% in 2022, and 3.7% in 2024, indicating issues with performance sustainability [2][9]. Managerial Strategy and Style Drift - The style drift has been evident since the current fund manager, Yao Yi, took over in January 2023, with the first quarterly report showing a complete focus on healthcare stocks, which accounted for over 50% of the net value [5][7]. - Despite achieving a total return of 46.78% and an annualized return of 15.85% under Yao Yi's management, the strategy has not aligned with the fund's original service-oriented theme, raising concerns about the appropriateness of the investment approach [7][9]. Regulatory and Market Implications - The fund's deviation from its contractual investment behavior raises compliance issues and may lead to unexpected risks for investors due to misinterpretation of the fund's theme [9][10]. - The fund's total size is 295 million yuan, with institutional investors holding 20.29%, indicating some level of external oversight, but individual investors remain the primary stakeholders [9].

Group 1 - The core viewpoint of the news is that the CSI 300 Pharmaceutical Index has shown significant growth, with a 10.82% increase over the past month, a 12.16% increase over the past three months, and a 23.32% increase year-to-date [1] - The CSI 300 Pharmaceutical Index is composed of listed companies in the pharmaceutical sector selected from the CSI 300 Index, reflecting the overall performance of these companies [1] - The index was established on December 31, 2004, with a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the CSI 300 Pharmaceutical Index are: Heng Rui Medicine (44.62%), Pian Zai Huang (9.73%), Yunnan Baiyao (7.8%), Kelun Pharmaceutical (6.59%), East China Pharmaceutical (6.11%), New Harmony (5.67%), Fosun Pharmaceutical (5.58%), Baili Tianheng (3.99%), Tong Ren Tang (3.87%), and China Resources Sanjiu (3.11%) [1] - The market share of the CSI 300 Pharmaceutical Index holdings is 70.72% from the Shanghai Stock Exchange and 29.28% from the Shenzhen Stock Exchange [1] - The composition of the index holdings by industry shows that drug formulations account for 66.89%, traditional Chinese medicine accounts for 27.44%, and raw materials account for 5.67% [1] Group 3 - The index sample is adjusted every six months, with adjustments implemented on the next trading day following the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with the sample adjustments, which occur at the same time as the regular sample adjustments [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]

金融界消息 截至2025年8月25日收盘，科伦药业（002422）报收于39.09元，上涨4.02%，换手率 1.69%，成交量22.09万手，成交金额8.51亿元。 资金流向方面，今日主力资金净流出6302.06万元，占比成交额7.4%。其中，超大单净流出3503.14万 元、占成交额4.12%，大单净流出2798.92万元、占成交额3.29%，中单净流出流入4567.22万元、占成交 额5.37%，小单净流入1734.84万元、占成交额2.04%。 科伦药业最新一期业绩显示，截至2025一季报，公司营业总收入43.90亿元、同比减少29.42%，归属净 利润5.84亿元，同比减少43.07%，扣非净利润5.64亿元，同比减少43.10%，流动比率2.033、速动比率 1.612、资产负债率27.48%。 天眼查商业履历信息显示，四川科伦药业股份有限公司，成立于2002年，位于成都市，是一家以从事医 药制造业为主的企业。企业注册资本159805.3372万人民币，实缴资本6436.822万人民币。公司法定代表 人为刘革新。 通过天眼查大数据分析，四川科伦药业股份有限公司共对外投资了47家企业，参与招投标项目 ...

四川科伦药业股份有限公司 关于归还暂时补充流动资金的可转债部分闲置募集资金的公告 证券代码：002422 证券简称：科伦药业 公告编号：2025-056 四川科伦药业股份有限公司（以下简称"公司"）于 2024 年 9 月 20 日召开 第八届董事会第三次会议和第八届监事会第三次会议，分别审议通过了《关于使 用部分闲置募集资金暂时补充流动资金的议案》，同意公司在确保募集资金投资 项目建设需求和募集资金使用计划正常进行的前提下，使用部分闲置募集资金不 超过人民币 16 亿元暂时补充流动资金，使用期限自董事会审议通过之日起不超 过 12 个月，到期前归还至募集资金专用账户。具体内容详见公司于 2024 年 9 月 24 日刊登于巨潮资讯网（http://www.cninfo.com.cn）上的《关于使用部分闲置 募集资金暂时补充流动资金的公告》（公告编号：2024-106）。 根据公司的资金使用安排，公司实际用于暂时补充流动资金的闲置募集资金 金额为人民币 16 亿元。截至 2025 年 8 月 25 日，公司已将上述用于暂时补充流 动资金的 16 亿元闲置募集资金全部归还至募集资金专用账户，使用期限未超过 12 ...

Group 1 - The core viewpoint of the article highlights the performance of the E Fund Healthcare Industry Mixed A Fund, which has shown significant returns over various time frames [1] - As of August 24, 2025, the latest net value of the fund is 4.7380 yuan, with a weekly return of -0.94%, a three-month return of 31.94%, and a year-to-date return of 55.55% [1] - The fund was established on January 28, 2011, and as of June 30, 2025, it has a total scale of 3.944 billion yuan [1] Group 2 - The top ten stock holdings of the fund include companies such as Heng Rui Medicine, Rejig Bio, Xin Li Tai, BeiGene-U, Hai Si Ke, and others, with a total holding percentage of 58.14% [1] - The fund manager is Yang Zhenshao, who oversees the investment strategy and portfolio management [1]